Tumor Infiltrating Lymphocytes in Breast Cancer: Why Is It Useful to Know?
- Author(s)
- Maley, SK; Khiroya, R; Provenzano, E; Salgado, R;
- Details
- Publication Year 2025-12,Volume 18,Issue #4,Page 725-733
- Journal Title
- Surgical Pathology Clinics
- Publication Type
- Review
- Abstract
- Stromal tumor infiltrating lymphocytes (sTILs) in breast cancer is an easily evaluable histopathological biomarker that is shown to be robust and reproducible with prognostic and predictive value in triple negative breast cancer (TNBC), HER2+, and high-risk luminal breast cancer. sTILs can be assessed using a light microscope on H&E-stained slides. sTILs also predict therapeutic response to chemotherapy and immunotherapy in the neoadjuvant setting, with higher sTILs score on baseline biopsies associated with higher pCR rates and better outcomes. sTILs have a potential role in therapy de-escalation/optimization strategies, and in the selection of patients for immunotherapy.
- Publisher
- Elsevier
- Keywords
- Humans; *Lymphocytes, Tumor-Infiltrating/pathology/immunology; Female; *Breast Neoplasms/pathology/immunology/therapy; Prognosis; Biomarkers, Tumor/analysis; Triple Negative Breast Neoplasms/pathology; Neoadjuvant Therapy; Breast cancer; Clinical outcomes and immunotherapy; HER2 positive breast cancer; Hormone receptor positive breast cancer; Stromal tumor infiltrating lymphocytes; Triple negative breast cancer
- Department(s)
- Laboratory Research
- Publisher's Version
- https://doi.org/10.1016/j.path.2025.07.003
- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2026-01-08 04:40:49
Last Modified: 2026-01-08 04:41:02